Geron (GERN) Amortizatization of Intangibles (2010 - 2026)
Geron (GERN) posted Amortizatization of Intangibles of $1.1 million for Q1 2026, down 25.97% sequentially from $1.4 million in Q4 2025, and down 51.63% YoY from $2.2 million in Q1 2025.
Geron (GERN) Amortizatization of Intangibles (2010 - 2026) Analysis & Trends
Geron has reported Amortizatization of Intangibles for 17 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 51.63% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 39.32% YoY) and the FY2025 annual result came in at $6.9 million, down 28.52% from the prior year.
- Amortizatization of Intangibles slipped to $1.1 million in Q1 2026 per GERN's latest filing, from $1.4 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $3.4 million in Q3 2023 and troughed at -$196000.0 in Q1 2022.
- A 5-year average of $1.8 million and a median of $1.7 million in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2026: Amortizatization of Intangibles jumped 3096.3% in 2023, then slumped 51.63% in 2026.
- Over 5 years, Amortizatization of Intangibles stood at $956000.0 in 2022, then surged by 194.46% to $2.8 million in 2023, then declined by 14.67% to $2.4 million in 2024, then plunged by 39.88% to $1.4 million in 2025, then retreated by 25.97% to $1.1 million in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $1.1 million, $1.4 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 708,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 708,000.00 |
| Jun 30, 2026 | 708,000.00 |
| Mar 31, 2026 | 1.07 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | 2.40 Mn |
| Dec 31, 2024 | 2.40 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 2.53 Mn |
| Jun 30, 2024 | 2.53 Mn |
| Mar 31, 2024 | 2.37 Mn |
| Mar 31, 2024 | 2.37 Mn |